pyrazoloacridine
Sponsors
Barbara Ann Karmanos Cancer Institute, Ohio State University Comprehensive Cancer Center, M.D. Anderson Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI)
Conditions
Brain and Central Nervous System TumorsBreast CancerDisseminated NeuroblastomaIntraocular MelanomaLiver CancerLung CancerMelanoma (Skin)Metastatic Cancer
Phase 1
Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme
CompletedNCT00006355
Start: 2000-05-31End: 2006-10-31Updated: 2012-05-03
Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma
TerminatedNCT00053950
Start: 2002-12-31Updated: 2013-04-09
Phase 2
Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma
CompletedNCT00005976
Start: 2000-05-31End: 2007-04-30Updated: 2013-06-03
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
CompletedNCT00003802
Start: 1999-02-28End: 2002-10-31Updated: 2012-12-17
Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer
CompletedNCT00003041
Start: 1997-07-31End: 2002-01-31Updated: 2013-01-31
Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer
CompletedNCT00002656
Start: 1995-10-31End: 2008-02-29Updated: 2013-04-29
Pyrazoloacridine in Treating Women With Metastatic Breast Cancer
CompletedNCT00002585
Start: 1994-02-28End: 2001-01-31Target: 20Updated: 2012-03-12
Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer
WithdrawnNCT00003714
Updated: 2012-02-22